Thoracic CT Analysis

Identification and volumetric quantification of anatomical structures within the

lungs
One page report with severity scores for emphysematous lung tissue and percentage of interlobar fissure completeness.
Visual representation of abnormal tissue for easy interpretation.

For CE use:
Produces reproducible CT values for pulmonary tissue, providing quantitative support for diagnosis, and follow-up examinations.
Supports the physician in the diagnosis, evaluation and documentation of pulmonary tissue images (e.g. abnormalities) from CT thoracic datasets.
Analysis provided includes segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation and reporting tools.

FDA use:
Provides reproducible CT values for pulmonary tissue which is essential for providing quantitative support for diagnosis and follow-up examination.
Supports physicians in the diagnosis and documentation of pulmonary tissue images (e.g. abnormalities) from CT thoracic datasets.

Results from a study shows that LungQ can:

Give accurate disease progression management with consistent and reproducible measurements across time (and acquisition protocols - EU CE only1).
Perform quantitative measurements within the identified sub-compartments on thoracic CTs, which aids clinicians in more accurate and precise diagnosis and timely management of the disease. This enables a personalized approach to treatment planning and monitoring of disease progression over time, potentially helping improve patient’s outcomes, documented with objective evidence1.
The intended clinical benefits of LungQ are:
- To aid a more precise diagnosis compared to the clinical standard of lung function testing,
- To follow disease progression over time with quantitative measurements.
- Allow for precise treatment planning.
- To help improve operational efficiency, allowing for potential reduction of clinical workload, quicker patient diagnosis, more effective treatment and reduced care costs.

LungQ